The landscape of psychiatric medicine is shifting as LB Pharmaceuticals moves its promising LB-102 into pivotal Phase 3 trials. Known as the NOVA-2 study, this research aims to validate a …
All Right Reserved. Designed and Developed by NewsBurrow Group